Shares of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) have earned a consensus rating of “Buy” from the ten analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $13.50.
A number of research firms have weighed in on SNDX. ValuEngine lowered Syndax Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 29th. Zacks Investment Research lowered Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. BidaskClub lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 24th. B. Riley set a $14.00 price objective on Syndax Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Nomura reiterated a “buy” rating and set a $16.00 price objective on shares of Syndax Pharmaceuticals in a research note on Sunday, August 11th.
In other Syndax Pharmaceuticals news, CEO Briggs Morrison bought 11,000 shares of the company’s stock in a transaction dated Thursday, October 10th. The shares were purchased at an average cost of $6.38 per share, for a total transaction of $70,180.00. 8.30% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter worth about $36,000. JPMorgan Chase & Co. boosted its holdings in Syndax Pharmaceuticals by 52.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,522 shares of the company’s stock worth $50,000 after buying an additional 1,902 shares during the last quarter. Ibex Investors LLC acquired a new stake in Syndax Pharmaceuticals in the 3rd quarter worth about $103,000. Athanor Capital LP acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter worth about $104,000. Finally, Sigma Planning Corp acquired a new stake in Syndax Pharmaceuticals in the 2nd quarter worth about $114,000. Hedge funds and other institutional investors own 63.16% of the company’s stock.
SNDX stock traded down $0.01 during midday trading on Monday, reaching $7.28. The stock had a trading volume of 85,300 shares, compared to its average volume of 159,148. The stock has a market cap of $197.85 million, a PE ratio of -2.49 and a beta of 2.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.09 and a current ratio of 4.09. The firm has a fifty day simple moving average of $6.89 and a two-hundred day simple moving average of $8.10. Syndax Pharmaceuticals has a 52-week low of $3.39 and a 52-week high of $11.11.
Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.07. The business had revenue of $0.38 million during the quarter, compared to analyst estimates of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 110.20% and a negative net margin of 4,013.45%. On average, sell-side analysts predict that Syndax Pharmaceuticals will post -1.9 EPS for the current fiscal year.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.